Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare Biotechnology

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc

Bullboard Posts

Comment by TheRock07on Nov 11, 2016 8:14am

101 Views

Post# 25448525

RE:Q3 Report...Very Good but US not so

Q3 is a slow quarter for dermatology sales.

Taking that into account, revenue was approximately $12 million CAD .

The Canadian segment is doing very well and very profitable.

The US business acquired in April 2015 is showing only modest growth and under performing , with significant operating losses.

Consequently an impairment was taken.

Turning this US segment around is now the main focus of management.

We are up for sale , so the US business might be sold in advance of that.

Cash levels remained at $31 million US or about $40 million CAD .

I foresee being sold at $7.50 per share, higher if they can sell the US business.

Bullboard Posts

Quantum eMotion leaps by 20 per cent after Becton Dickinson deal